ArticleBreast cancer (Dove Medical Press)2026
Development and Preliminary Validation of a Wearable Tumor Treating Fields Device for Breast Cancer Therapy.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tumor treating fields (TTFields) is a novel non-invasive tumor treatment method that can inhibit the growth of a variety of tumors with few side effects. However, the devices used for TTFields therapy are relatively scarce and has great limitations in scientific research and clinical application scenarios. Objective: The objective of this study is to address the challenge posed by the large size of TTFields therapeutic devices, which adversely affect patient mobility, quality of life, and treatment adherence. Furthermore, this study aims to explore the potential of TTFields as a therapeutic approach for breast cancer treatment, evaluating its efficacy and feasibility in extracranial applications. Methods: In this study, we designed a wearable device called TTF-Backpack integrates a stimulator for generating alternating electric field (0~250 kHz, 0~40 mA). In addition, we planned circuit experiments to evaluate the electrical performance of the device and validated its efficacy by establishing rat models of breast cancer syngeneic graft. The models were treated with alternating electric fields (frequency 250 kHz, intensity 1-1.5 V/cm) for 24 hours daily over 7 days. Results: The maximum output voltage of TTF-Backpack is approximately 55V with the frequency bandwidth of 0~250 kHz, and its current can reach 40 mA. Furthermore, animal experiment results indicated that TTF-Backpack can inhibit the progression of breast cancer. Analysis of tumor tissue sections demonstrated that the mRNA levels of ki67, the mRNA and protein expression levels of the pro-apoptotic gene Bax upregulated, while the protein expression level of the anti-apoptotic marker Bcl2 downregulated significantly. Conclusion: This study demonstrates the feasibility and preliminary efficacy of a novel wearable TTFields device for breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.